Hydrogest DS 500 mg/2 ml (IM Injection)
2 ml ampoule: ৳ 650.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Hydroxyprogesterone caproate |
| Company | Renata limited |
| Also available as |
Product Title and Categories
- Hydrogest DS
- Medicine
- Hormone Preparations
Dimensions
- N/A
Color Options
- N/A
Functions
- Reduction of Risk of Preterm Birth
- Prevention of Preterm Labor
- Synthetic Steroid Hormone
- Prevention of Thrombosis or Thromboembolic Disorders
- Maintenance of Pregnancy
- Regulation of Gene Transcription
- Anti-inflammatory Effect
- Prevention of Fluid Retention
Materials
- Synthetic Steroid Hormone
- 17a-hydroxyprogesterone
- Caproic Acid (Hexanoic Acid)
- Progesterone Receptors
Technical Specifications
- Dosage: 250 mg or 500 mg once weekly
- Age Range: 16 years or older
- Administration: Intramuscular
- Pregnancy Category: B
- Storage Temperature: 15°C to 30°C
Design Elements
- Ampoule
- Alcohol Swab
- 2 ml Syringe
- Viscous and Oily Solution
Usability Features
- Weekly Administration
- Injection Site Preparation
- Slow Injection Recommended
- Applying Pressure to Injection Site
Indications
- Reduction of Risk of Preterm Birth in Women with a Singleton Pregnancy
- Prevention of Preterm Labor in Singleton Pregnancy
Description
- Similar to Medroxyprogesterone Acetate and Megestrol Acetate
- Ester Derivative of 17a-hydroxyprogesterone formed from Caproic Acid
Pharmacology
- Progesterone Receptors in Uterus, Ovaries, Breasts, and CNS
- PR-A and PR-B Isoforms
- Gene Transcription Regulation
- Uterine Quiescence Stabilization
Dosage & Administration
- Administer Intramuscularly
- Injection Site Preparation
- Draw up 1 ml of Drug into a 2 ml Syringe
- Injection in Upper Outer Quadrant of Gluteus Maximus
- Applying Pressure to Injection Site
Contraindications
- Thrombosis or Thromboembolic Disorders
- Breast Cancer or Other Hormone-Sensitive Cancer
- Abnormal Vaginal Bleeding
- Cholestatic Jaundice of Pregnancy
- Liver Tumors or Active Liver Disease
- Uncontrolled Hypertension
Side Effects
- Injection Site Reactions
- Hives
- Itching
- Nausea
- Diarrhea
- Blood Clot Symptoms
- Allergic Reactions
Pregnancy & Lactation
- Pregnancy Category B
- No Adequate and Well-controlled Studies in First Trimester
- Detectable Amounts of Progestins in Breast Milk
- Discontinue Drug at 37 Weeks of Gestation or Upon Delivery
Precautions & Warnings
- Thromboembolic Disorders
- Decreased Glucose Tolerance
- Fluid Retention
- Depression
- Jaundice
- Hypertension
Use in Special Populations
- Not Indicated for Use in Pediatric Patients
- Safety and Efficacy Not Established in Pediatric and Postmenopausal Patients
- Effect on Hepatic and Renal Impairment Not Evaluated
Overdose Effects
- No Adverse Events Associated with Overdosage Reported
Therapeutic Class
- Hormone Preparations for Other Uses
Storage Conditions
- Controlled Room Temperature
- Protect from Light
- Keep Out of Reach of Children